



In the Specification:



Please replace the paragraph beginning at page 10, line 35 through page 11, line 7, with the following amended paragraph:

The tripeptide sequence of TRI 50b has three chiral centres. The Phe residue is considered to be of (R)-configuration and the Pro residue of natural (S)-configuration, at least in compounds with commercially useful inhibitor activity; the Mpg residue is believed to be of (R)-configuration in isomers with commercially useful inhibitor activity. Thus, the active, or most active, TRI 50b stereoisomer is considered to be of R,S,R configuration and may be represented as:




Please replace the paragraph beginning at page 35, line 26 through page 36, line 1, with the following amended paragraph:

The aa¹ moiety of the salt is preferably of (R)-configuration. The aa² moiety is preferably of (S)-configuration. Particularly preferred salts have aa¹ of (R)-configuration and aa² of (S)-configuration. The chiral centre -NH-CH(R¹)-B- is preferably of (R)-configuration. It is considered that commercial formulations will have the chiral centres in (R,S,R) arrangement, as for example in the case of salts of Cbz-Phe-Pro-BoroMpg-OH:




Please replace the paragraph beginning at page 57, line 1, with the following amended paragraph:



LDA = lithium diisopropylamide

LiHMDS = lithium hexamethyldisilazane, also known as lithium bis(trimethylsilyl)amide



LDA = lithium diisopropylamide

LiHMDS = lithium hexamethyldisilazane, also known as lithium bis(trimethylsilyl)amide